Coordinatore |
Organization address
address: Moutstraat 100 contact info |
Nazionalità Coordinatore | Non specificata |
Totale costo | 8˙352˙757 € |
EC contributo | 6˙414˙915 € |
Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
Code Call | FP7-IC |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-01-01 - 2012-06-30 |
# | ||||
---|---|---|---|---|
1 |
AGFA HEALTHCARE N.V.
Organization address
address: Moutstraat 100 contact info |
BE (GENT) | coordinator | 0.00 |
2 |
Averbis GmbH
Organization address
address: Stefan-Meier-Strasse contact info |
DE (Freiburg) | participant | 0.00 |
3 |
EMPIRICA GESELLSCHAFT FUER KOMMUNIKATIONS- UND TECHNOLOGIE FORSCHUNG MBH
Organization address
address: OXFORDSTRASSE contact info |
DE (BONN) | participant | 0.00 |
4 |
GAMA/SOFIA LTD
Organization address
address: Tintyava contact info |
BG (SOFIA) | participant | 0.00 |
5 |
HAUTE ECOLE SPECIALISEE DE SUISSE OCCIDENTALE
Organization address
address: RUE DE LA JEUNESSE contact info |
CH (DELEMONT) | participant | 0.00 |
6 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
7 |
IZIP A.S.
Organization address
address: HVEZDOVA contact info |
CZ (PRAHA 4) | participant | 0.00 |
8 |
LES HOPITAUX UNIVERSITAIRES DE GENEVE
Organization address
address: RUE GABRIELLE PERRET GENTIL contact info |
CH (GENEVE 14) | participant | 0.00 |
9 |
LINKOPINGS UNIVERSITET
Organization address
address: CAMPUS VALLA contact info |
SE (LINKOPING) | participant | 0.00 |
10 |
MD ACCESS AS
Organization address
address: Hvezdova contact info |
CZ (Prague) | participant | 0.00 |
11 |
TECHNOLOGIKO EKPEDEFTIKO IDRIMA LAMIAS
Organization address
address: 3 KLM PALAIAS ETHNIKIS ODOU contact info |
EL (LAMIA) | participant | 0.00 |
12 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE contact info |
DE (FREIBURG) | participant | 0.00 |
13 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour contact info |
CH (GENEVE) | participant | 0.00 |
14 |
UNIVERSITY COLLEGE LONDON
Organization address
address: Gower Street contact info |
UK (LONDON) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
In about half a century of antibiotic use, unexpected new challenges have come to light: fast emer-gence of resistances among pathogens, misuse and overuse of antibiotics; direct and indirect re-lated costs. Antimicrobial resistance results in escalating healthcare costs, increased morbidity and mortality and the emergence or reemergence of potentially untreatable pathogens. In this context of infectious diseases we will (1) detect patient safety issues, (2) learn how to prevent them and (3) actually prevent them in clinical cases. We will detect harmful patterns and trends using clinical and operational information from Clinical Information Systems (CIS). This will bendone through the 'view' of a virtualized Clinical Data Re-pository (CDR), featuring, transparent access to the original CIS and/or collection and aggregation of data in a local store. Text, image and structured data mining on individual patients as well as on populations will learn us informational and temporal patterns of patient harm. This knowledge will be fed into a Medical Knowledge Repository and mixed with knowledge coming from external sources (for example guidelines and evidences). After editing and validating, this knowledge will be used by andecision support and monitoring tool in the clinical environment to prevent patient safety issues and report on it.nOutcomes and benefits, both clinical and economical will be measured and reported on. Innovation within this project lays in the virtualization of Clinical Data Repository through ontology mediation, the advanced mining techniques, the reasoning engine and the consolidation of all these techniques in a comprehensive but open framework. This framework will be implemented, focused on infectious diseases, but will be applicable for all sorts of clinical cases in the future.